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Abstract
As the secretory source of vitamins, peptides and hormones for neurons, the choroid plexus (CP)
epithelium critically provides substances for brain homeostasis. This distributive process of
cerebrospinal fluid (CSF) volume transmission reaches many cellular targets in the CNS. In ageing
and ageing-related dementias, the CP-CSF system is less able to regulate brain interstitial fluid. CP
primarily generates CSF bulk flow, and so its malfunctioning exacerbates Alzheimers disease (AD).
Considerable attention has been devoted to the blood-brain barrier in AD, but more insight is
needed on regulatory systems at the human blood-CSF barrier in order to improve epithelial
function in severe disease. Using autopsied CP specimens from AD patients, we
immunocytochemically examined expression of heat shock proteins (HSP90 and GRP94), fibroblast
growth factor receptors (FGFr) and a fluid-regulatory protein (NaK2Cl cotransporter isoform 1
or NKCC1). CP upregulated HSP90, FGFr and NKCC1, even in end-stage AD. These CP
adjustments involve growth factors and neuropeptides that help to buffer perturbations in CNS
water balance and metabolism. They shed light on CP-CSF system responses to ventriculomegaly
and the altered intracranial pressure that occurs in AD and normal pressure hydrocephalus. The
ability of injured CP to express key regulatory proteins even at Braak stage V/VI, points to plasticity
and function that may be boosted by drug treatment to expedite CSF dynamics. The enhanced
expression of human CP 'homeostatic proteins' in AD dementia is discussed in relation to brain
deficits and pharmacology.
Review
Choroid plexus impact on Alzheimer's disease
Accumulating evidence supports the idea that continually
decreasing choroid plexus (CP) function in advanced age-
ing exacerbates Alzheimer's disease (AD). As part of a new
paradigm to explain brain interstitium deterioration in
age-related dementias, increasingly more attention is
being paid to the role of compromised blood-CSF [1] and
blood-brain [2] barriers. Structural alterations and func-
tional failures in CP as well as brain capillary transport
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systems adversely affect fluid dynamics and composition
[3,4]. This review treats mainly CP dysfunction and the
compensatory reactions that occur in this epithelium in
AD.
Efficient CSF turnover is essential for a healthy brain. It
depends upon an exquisite balance between CSF forma-
tion and reabsorption [5]. Compromised secretory phe-
nomena at the CP 'upstream' predispose the brain to AD-
type problems. On the other hand, defective clearance of
CSF at the arachnoid membrane 'downstream' leads to
normal pressure hydrocephalus (NPH) [6]. The pivotal
role of the CP in CSF homeostasis and brain viability
becomes more evident when the system fails. More infor-
mation is needed to evaluate how diminishing choroidal
functions affect the surrounding brain in the face of AD
and other dementias.
Brain fluid homeostasis: The role of CSF volume 
transmission
In serving the brain's metabolic needs by supplying 'bio-
chemical goods', the CP uses CSF as a conduit for convect-
ing substances [7]. Numerous solutes ranging from ions
to large proteins are entrained in the CSF that percolates
through the ventricular axis (Fig. 1). CSF intimately con-
tacts the periventricular brain tissue with which it
exchanges materials bidirectionally by diffusion and bulk
flow. Continually undergoing chemical modification as it
flows downstream, the CSF completes the volume trans-
mission process [7] by draining into venous blood at dis-
tal arachnoidal sites (Fig. 1).
Reduced formation of CSF and stagnated flow in ageing
and AD [4] limits the delivery of substances to neurons.
This debilitates brain function [3]. Numerous proteins are
synthesized and secreted by CP into CSF. Other sub-
stances are transported from blood. Table 1 overviews
molecules normally distributed by the CP-CSF nexus.
Arginine vasopressin (AVP) is a neuropeptide synthesized
by CP epithelium and secreted into CSF [8,9]; it regulates
CSF formation and modulates hippocampal memory
mechanisms [10,11]. Growth factors foster cell growth,
blood supply and water balance [1]. Trace element distri-
bution across CP is complex and involves many mecha-
nisms. Iron transport into CSF, for example, is regulated
by several proteins [1] alterations in which may predis-
pose to amyloidogenesis [12]. Vitamins B and C are
actively transported at the blood-CSF barrier [13]. This
stabilizes their concentration in CSF, except in late-onset
AD [14]. The net entry of nucleoside bases into CSF is also
determined by active transporters in CP [15,16]. Cysteine
protease inhibitors like cystatin C are synthesized in CP
epithelium for transport into CSF [17]. Hormones such as
leptin and prolactin are translocated from plasma to CSF
by saturable choroidal receptors [18,19]. Overall it is strik-
ing that the CP-CSF interface engages in such prolific
transport. Disease-associated interference with CP trans-
porters and volume transmission limits the availability of
CSF molecules for the brain [1,20].
Structural and functional damage to the choroid plexus in 
AD
Structure intimately relates to function in various epithe-
lia. Therefore it is useful to analyze histopathological
damage to CP at various stages of AD in order to clarify the
onset of functional losses at the blood-CSF barrier. Ageing
and AD cause similar degeneration in CP. Structural
changes in AD though are usually greater than in non-
demented control counterparts [21]. Serot and colleagues
have delineated modifications in the choroidal epithe-
lium, stroma and vessels in AD subjects [22-24]. There are
substantial alterations in all tissue compartments.
Several features characterizing the CP in AD are high-
lighted in Table 2. Epithelial cells are typically truncated,
with an average volume 70% of that at birth. Such epithe-
lial atrophy likely affects cellular functions. Particularly
prominent is an increase in the number of Biondi bodies
in AD [25]. These bodies are fibrillar inclusions in the
cytoplasm of very old epithelial cells. Lipofuchsin vacu-
oles also occur frequently in the cytoplasm. The basement
membrane underlying the cell often thickens to 350 nm,
compared to a much thinner membrane (ca. 100 nm) in
neonates [21]. Another liability in AD is immunological
deposition of C1q, IgG and IgM along the epithelial base-
ment membrane. As fibrosis intensifies with age and dis-
ease, the stroma attains a thickness of a few tenths of a
micron [21]. At the inner core of the choroidal villus, the
blood vessel walls thicken. This coincides with the appear-
ance of amyloid, hyaline bodies, psammomas and calcifi-
cations. Altogether, the histopathologic changes in CP
compartments point to grossly-declining secretory func-
tions in AD. Such structural abnormalities coincide with
diminished CSF production in ageing [26] and AD
patients [4].
Due to the functional nexus of the CSF with brain intersti-
tial fluid, the neuronal microenvironment in AD is
impacted by markedly altered transport and permeability
in CP. When neurodegenerative diseases, ischemia
[27,28] and elevated pressure [29,30] inflict damage on
the choroidal epithelium, there are resultant adverse
changes in CSF composition and volume. Because neu-
rons are sensitive to instabilities in CSF dynamics and
constituents, it is important to assess the nature and pro-
gression of disrupted CP function in chronic diseases. In
view of the expanding number of AD victims, it is timely
to consider patterns of expression of chaperone proteins,
receptors and transporters in CP at various Braak stages.
Such information may abet future attempts to stabilizeCerebrospinal Fluid Research 2004, 1:3 http://www.cerebrospinalfluidresearch.com/content/1/1/3
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Schema for CSF convection of water and solutes: Arterial blood perfusing the choroid plexus continually provides water, ions  and organic substrates for the CP epithelial cells to form the CSF that underlies volume transmission Figure 1
Schema for CSF convection of water and solutes: Arterial blood perfusing the choroid plexus continually provides water, ions 
and organic substrates for the CP epithelial cells to form the CSF that underlies volume transmission. Manufactured by the CP 
epithelium as the result of numerous transport processes, the CSF is actively secreted into the ventricles. In transit through 
the ventricular cavities to the arachnoid drainage sites, the CSF exchanges anabolites and catabolites with brain interstitial fluid. 
As a result, trophic and signaling molecules are delivered (blue arrow) to the neurons and, concurrently, toxic waste products 
and unneeded proteins are removed (red arrow) by CSF 'sink action' on the brain. The permeable ependymal membrane 
allows bi-directional diffusion of beneficial and harmful molecules. Bulk flow or volume transmission of CSF is thus essential in 
effecting the homeostasis of fluid composition.
Table 1: Substances distributed to brain by transport at the blood-CSF gateway
Class or group Examples Functions References
Neuropeptides Arginine vasopressin Regulation of CSF formation [8–11]
Growth factors Basic fibroblast growth factor Integration of water balance [55, 104]
Trace elements Iron Enzyme function in neurons/glia [1, 12]
Vitamins Ascorbate & folate Antioxidants & co-factors for brain [13, 14]
Nucleoside bases Thymidine Nucleic acids & drug transport [15, 16]
Protease inhibitors Cystatin C Neuroprotection after ischemia [1, 17]
Hormones Prolactin & leptin Modulation of hypothalamus [18, 19]Cerebrospinal Fluid Research 2004, 1:3 http://www.cerebrospinalfluidresearch.com/content/1/1/3
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choroid plexus functional integrity perturbed in early AD
dementia.
Choroid plexus defense against insults in ageing and 
degeneration
The CP is multifunctional, performing a wide range of
homeostatic functions for the CNS [5]. CSF homeostasis
is mediated mainly by CP. It involves the activity of many
protein transporters and receptors at the basolateral and
apical surfaces of the epithelial cells [31]. In addition to
providing organic solutes for nutritive and trophic sup-
port of the brain, the CP secretions into the ventricles
adjust the pH, osmolality, [K+] and immune molecule
content of the CNS extracellular fluid [7]. Accordingly,
healthy neurons are fundamentally dependent upon
transport at the blood-CSF and blood-brain interfaces.
Moreover to provide steady neuroprotection by regulating
the extracellular milieu, the CP must protect itself against
various stressor agents that build up during ageing and
disease. There have been few investigations of the home-
ostatic systems within CP that stabilize choroidal
functions in the face of ageing and AD. We have explored
some candidate systems for compensatory responses by
CP. Cytoplasmic heat shock proteins chaperone and per-
form housekeeping to maintain a healthy steady-state
intraepithelial milieu [1,32]. Growth factors critically
minimize cell morbidity and mortality [27]. Fluid-regulat-
ing proteins correct ion and water imbalances that occur
in neurodegenerative diseases. Consequently our hypoth-
esis is that the upregulation of certain proteins in CP (such
as those discussed above) thwarts certain untoward effects
of ageing and disease progression. The protein expression
aspect of the hypothesis was tested by analyzing immu-
nostaining patterns in human CP specimens from
patients with varying severity of AD.
Analyses of human choroid plexus: Usefulness and 
challenges
It is difficult to functionally assess the CP in vivo [30,33],
particularly in man. Alternatively one can evaluate the sta-
tus of human CP in disease by analyzing autopsied tissues
for variable protein expression [34]. Such findings are
compared to appropriate age-matched controls. Immu-
mocytochemical and biochemical data gleaned from
human CP highlight directions to pursue with living ani-
mal models: transgenic mice with an AD phenotype or
aged rats with CSF pathophysiology. Because protein
expression relates to disease progression, it is essential to
standardize grading for the severity of AD in subjects. We
use a modified Braak & Braak staging system [35]: stages
I/II (mild; disease involves hippocampus and entorhinal
cortex); stages III/IV (moderate; AD spreading to the rest
of the limbic lobe, e.g., amygdala); and stages V/VI
(severe; further AD spreading to the prefrontal neocortex).
Information about functional proteins in human CP is
scarce. However protein expression was recently analyzed
in autopsied lateral ventricle CP from normal adult brains
and in those with confirmed AD [36,37]. The ages investi-
gated were generally between 65 and 90 yr for all subjects.
Control individuals typically died from cardiac disease or
tumors. AD specimens covered all Braak stages. Causes of
the AD deaths were usually cardiac complications or
pneumonia [37]. Fortunately the postmortem intervals
(mainly between 2 and 18 hr) did not affect antibody
staining [37]. For specimen quality it is desirable to
procure choroidal tissues quickly after death. Human CP
banks are needed to systematically catalog tissues from
various stages of AD.
Regulation of CP 'homeostatic proteins' in health and 
disease
Ageing and AD dementia tax the CP and other CNS trans-
port interfaces. In late life the deteriorating brain presents
many potentially-destructive metabolites to the CSF for
multi-site excretion into blood. The greater burden of
macromolecule disposal in AD occurs when CP and
arachnoid membrane, due to ageing debilities, are less
able to transfer solutes. Nevertheless the CP seemingly
attempts to maintain its 'epithelial soundness' when chal-
lenged to perform additional cleansing acts for the brain
extracellular fluid (CSF).
In healthly, young adults the CP epithelium sensitively
acclimates to chemical and physical distortions in blood,
CSF and parenchyma. Following cortical stabbing in rats,
the CP upregulates TGFβ presumably to provide this CSF-
borne growth factor for repairing the injury [38]. A similar
phenomenon occurs with IGF-II [39], which is manufac-
tured in the CNS mainly by CP. In diabetes there is
enhanced expression of the NKCC1 cotransporter in CP
for adjusting CSF dynamics and water distribution [40].
Such compensatory responses at the blood-CSF barrier in
early adulthood raise the question about CP's ability in
later life, when besieged by the deficits of aging and AD,
Table 2: Pathological changes in choroid plexus in Alzheimer's 
diseasea
Epithelial atrophy (↓ cell size by 1/3)
↑ Biondi bodies
Lipofuchsin vacuoles
Basement membrane thickening (3-fold ↑)
↑ Stromal fibrosis
IgG and IgM depositions
aDescribed by Serot and colleagues in refs. 22–24Cerebrospinal Fluid Research 2004, 1:3 http://www.cerebrospinalfluidresearch.com/content/1/1/3
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to adequately respond by expressing certain 'homeostatic
proteins'.
Accordingly to assess pathophysiologic consequences of
AD we investigated human CP's ability to upregulate cer-
tain functional proteins (as distinguished from structural
ones) in advanced states of AD dementia. With advancing
knowledge about intricate cell physiology (coordinated
interactions among organelles, cytoplasm and mem-
brane-bound proteins) it is relevant to evaluate compo-
nents of cellular homeostasis. The term 'homeostatic
proteins'refers to chaperones, receptors and transporters
that stabilize the internal environment of the cell. CSF sta-
bility depends in large part upon CP epithelial homeosta-
sis. Our group has analyzed several 'homeostatic proteins'
involved in CP intracellular milieu stabilization:
Heat shock proteins
A wide spectrum of protection against neurodegeneration
is provided by HSPs. The list of protective effects bestowed
by HSP molecules is diverse and includes: accelerated deg-
radation of misfolded proteins, maintenance of mem-
brane lipid integrity, prevention of deleterious protein
aggregation, and preclusion of damage to the transla-
tional apparatus [41,42]. HSPs are also known as 'stress
proteins' due to their role in shepherding adaptive
responses to stressors such as ischemia, trauma, fever,
dehydration, hydrocephalus and other brain disorders.
To evaluate human CP expression, we selected HSPs over-
expressed in AD brains: GRP94 and HSP90. In contrast to
previously found upregulation in brain, there was down-
regulated GRP94 in lateral ventricle CP. In aged controls
there was abundant staining in the epithelial cytoplasm
and stroma (Fig. 2, top left). However in AD there was a
striking decrease in immunostaining of GRP94 choroidal
tissues (Fig. 2, top right). GRP94 is an atypical HSP in
responding specifically to glucose deprivation rather than
to generalized intracellular oxidative stress. In AD the
opposite responses in GRP94 expression by CP vs. brain
are interesting but not unexpected because secretory epi-
thelium has biochemical characteristics fundamentally
different from neurons. GRP94 chaperones protein fold-
ing, especially in endoplasmic reticulum [43]. Underex-
pressed GRP94 in CP of AD subjects may render the
reticulum vulnerable to unfolded proteins.
In the case of HSP90, the reverse pattern of GRP94 was
observed. There was faint staining of non-AD tissues (Fig.
2, bottom left) but strong expression in epithelial cyto-
plasm in AD CP (Fig. 2, bottom right). Multiple effects can
be induced by a particular HSP. By complexing with sev-
eral intracellular protein kinases, HSP90 could alter CSF
secretion; and by inducing the heme-regulated e1F-2
alpha kinase, the overexpressed HSP90 may downregulate
gene transcription [44]. Another possible effect of HSP90
is to beneficially accelerate clearance (reabsorption) of Aβ
peptide by CP. Such facilitation occurs in the microglial
handling of Aβ [45]. It would be worthwhile to pursue the
role of CP HSPs in removing Aβ from CSF.
FGF peptides and receptors
The FGF superfamily of peptides and its multiple recep-
tors in CP, ependyma, and brain, modulate many actions
on neurons and non-neural cells [30]. FGF2, or basic FGF,
is prototypic of the family. CP synthesizes and releases
FGF2 into CSF. Choroidally-secreted FGF2 stimulates
receptors (FGFr) nearby in the CP apical membrane [9]
and at more distant sites in the brain parenchyma [46].
FGF/FGFr is apparently unique among growth factors in
directly effecting balance in the brain fluids, including the
formation of CSF. This is relevant to AD in which brain
FGF is increased [47] and CSF turnover declines [1,4,6].
FGF and FGFr are also fundamentally important in foster-
ing neuron generation from stem cells in the subventricu-
lar zone (SVZ). This requires coordination between the
CP-CSF and periventricular regions [46,48]. Pharmaco-
logical manipulation of SVZ stem cells is potentially
important at all stages of life. For pathological and thera-
peutic reasons, therefore, it is important to delineate FGFr
expression patterns and their significance in i) ontogeny,
ii)  normal adult maintenance, and iii)  neurodegenera-
tion.
i) Ontogeny
Receptor plasticity in aging and AD is better seen in light
of information on FGF/FGFr expression dynamics in early
life. In the fetus the formation of CP, neuronal stem cells
and brain is promoted by CP growth factor secretion and
CSF distribution [46,49]. Intense activity of FGF/FGFr fig-
ures prominently in CNS viability and expansion. Expres-
s i o n  o f  F G F r - 2  a n d  - 3  i n  m u r i n e  C P  i s  m a i n t a i n e d
prenatally, whereas FGFr-1 and -4 are present during the
2nd  but not 3rd  gestational week [49]. FGF peptides
released from CP use autocrine and paracrine mecha-
nisms to stimulate various forms of FGFr expressed by CP
epithelium. Specific functions of the four different recep-
tor isoforms need elucidation. Despite limited data for CP
FGFr expression patterns in aging, the genetic regulation
of FGFr during embryonic life [49] suggests the potential
to pharmacologically enhance FGFr expression in AD. The
goal in filling these knowledge gaps about FGFr is to
attain more efficacious treatment of injuries to the brain
interior.
FGF2 derived from CP is also conveyed by CSF bulk flow
to the fetal germinal matrix where it acts on stem cell FGFr
to promote neuronal maturation [46]. By this endocrine-
like mechanism, the CSF-mediated distribution of FGF2Cerebrospinal Fluid Research 2004, 1:3 http://www.cerebrospinalfluidresearch.com/content/1/1/3
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and other peptides plays a prominent role in 'spawning'
new neurons in the periventricular regions. Distorted CSF
volume and flow in hydrocephalus interferes with the CSF
provision of FGF2 to FGFr on stem cells in the SVZ [46].
Brain malformation ensues. Clearly the orderly function
of the CP-CSF system, e.g., the programmed secretion and
distribution of growth factors, is essential to normal CNS
development.
ii) Adult maintenance and response to stressors
The FGF/FGFr system also has a key role in adult CNS
fluid homeostasis. CP helps the brain adapt to alterations
Heat shock (stress) protein expression in human CP: Formalin-fixed, paraffin-embedded specimens (8–10 micrometers thick)  were de-paraffinized and rehydrated Figure 2
Heat shock (stress) protein expression in human CP: Formalin-fixed, paraffin-embedded specimens (8–10 micrometers thick) 
were de-paraffinized and rehydrated. Sections were incubated overnight with antibodies against HSP90 (1/500; SPA830) and 
GRP94 (1/500;SPA850) and stained by the ABC technique (Vectastain Elite ABC peroxidase). Deposition of the brown chro-
mogen (diaminobenzidine) reaction product was either substantially reduced by preabsorption blocking or virtually eliminated 
by omission of either primary or secondary antibodies. Slides were assessed blindly for staining intensity and distribution [37]. 
See text for description of localization and interpretation. For each HSP, images are representative of 10 AD specimens and 5 
age-matched controls.Cerebrospinal Fluid Research 2004, 1:3 http://www.cerebrospinalfluidresearch.com/content/1/1/3
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in blood composition and flow. In otherwise healthy
young adults, the imposition of dehydration or sudden
ischemia upon the CNS elicits striking adaptive changes in
CP epithelium. To endure insults by chemical or physical
stressors [29], it is critical that CP viability be maintained
so that the brain can continue to benefit from 'homeo-
static adjustments' in transport phenomena at the blood-
CSF barrier [50]. Growth factors are an integral part of
these adaptive responses to stress. Dehydration and
ischemia are common to aging and AD. Elucidation of
CP-CSF growth factor responses to these disorders in nor-
mal adults should enhance our perspective on homeo-
static capabilities in AD.
Dehydration seriously threatens CNS functions. Adjust-
ments to dehydration in the healthy adult brain feature
ion and water redistribution among fluid compartments.
These compensatory responses to plasma hyperosmolal-
ity stabilize neuronal and interstitial volumes. Brain 'bar-
riers' or transport interfaces are sites for the fluid
homeostatic mechanisms. A working model for the resto-
ration of fluid balance is offered: Dehydration or hyperos-
molality upregulates the FGF2 and AVP peptides in CP
[51,52]. FGF2 released by CP binds in an autocrine man-
ner to FGFr. Such FGFr stimulation likely promotes AVP
release from CP epithelium [9]. The extruded AVP then
binds V1 receptors in CP to regulate ion transport [53]
and fluid production [10,54]. FGF2 works in concert with
AVP to control fluid movement across the blood-CSF bar-
rier [51,55]. Interestingly in AD there are upregulated
receptors for FGF (Fig. 3) and AVP [56] in human CP, pre-
sumably in response to fluid imbalance. Cumulative evi-
dence points to co-localized growth factors and
neuropeptides jointly stabilizing brain fluids after per-
turbed osmolality and volume.
Ischemia is another disorder with neuropathological con-
sequences that are mitigated by growth factor upregula-
tion or administration [57]. Bilateral carotid artery
occlusion in young adult rats for 6–10 min wreaks dam-
age to tissues surrounding the lateral ventricles [58,59].
Hence severe transient forebrain ischemia (TFI) injures
the lateral plexus as well as the hippocampus [60]. How-
ever peptides such as FGF2 and TGFβ defend the forebrain
interior against ischemic and hypoxic insults [57,58,61].
Although TFI with hypotension (40 mmHg) destroys
many choroidal epithelial cells [60], there is a role by
growth factors to efficiently repair the breached blood-
CSF barrier [60]. Restitution of the epithelial lining of the
choroidal villi within several hours post-stroke [60]
implies the importance of a functional CP for CNS viabil-
ity. Upregulated secretion of FGF2, TGFβ [58] and other
growth factors by CP [27] undoubtedly protects the
blood-CSF barrier and periventricular brain against com-
FGF receptor expression in human CP: Lateral ventricle plexuses obtained from pathologically-confirmed AD subjects were  immersion-fixed in paraformaldehyde, cryoprotected and stored at -70°C Figure 3
FGF receptor expression in human CP: Lateral ventricle plexuses obtained from pathologically-confirmed AD subjects were 
immersion-fixed in paraformaldehyde, cryoprotected and stored at -70°C. CP segments were free-floated for 72–96 hr in a 1/
500 polyclonal antibody against the FGFr, which recognizes all FGF receptor subtypes. Specific staining was established by anti-
body omission/preabsorption [36]. ABC peroxidase/diaminobenzidine technique was used. Arrowhead points to small punc-
tated dots of immunoreactivity. Localization of FGFr is described in text. Images are typical of those obtained from 8 controls 
and 8 AD specimens, respectively.Cerebrospinal Fluid Research 2004, 1:3 http://www.cerebrospinalfluidresearch.com/content/1/1/3
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promised blood flow. A time-course analysis of FGF2-
FGFr expression in the aging vs. diseased CP will reveal
how the blood-CSF interface responds to reduced blood
flow in NPH and AD [62,63].
iii) Neurodegeneration
FGF2 titers and FGFr receptor densities in degenerating
CNS compartments provide insight on adaptive
responses. FGF2 concentration is augmented in the AD
brain [47]. Moreover with immunostaining and ELISA it
was demonstrated that FGF2 levels in CP are sustained in
AD [36]. It is thus probable that FGF2 and other factors
secreted into CSF of aged adults are essential to forestall-
ing harm to neurons in ischemia. A CSF feedback control
system for the choroidal production of FGF2 has been
suggested by FGFr identification in young adult rat CP [9].
An elevated level of FGF2 in AD brains [47] is interpreted
as peptide sequestration from CSF [36], thereby lowering
CSF concentration. Diminished CSF FGF2 could cause a
compensatory increase in CP FGFr expression. Testing this
postulate, we found enhanced staining for FGFr in AD CP
epithelium (Fig. 3). This observation supports a role of the
CP-CSF system in responding to increased demands by
brain for FGF2. To build this model, information is
needed for FGF2 and FGFr isoforms in various regions of
the CNS and CSF at specific stages of dementia.
FGF2 has an interesting relationship with amyloid. A
worthwhile goal is to probe mechanisms of FGF2 interac-
tion with amyloid in neuronal networks, extracellular
matrix and CP-CSF. FGF2 co-localizes with several chem-
ical forms of amyloid. Neuronal coexistence of FGF2 and
amyloid precursor protein (APP) [64,65] intimates a func-
tional relationship between FGF2 and APP, perhaps in
post-injury regeneration. FGF2 also minimizes metabolic
injury caused by Aβ peptides. It was initially observed that
FGF2 applied to cultured neurons reduced neurotoxicity
of aggregated Aβ [66]. More recent findings confirm
FGF2's benefit in abolishing neurotoxicity produced by
Aβ1-43 [67] and attenuation of oxidative stress in hippoc-
ampal neurons induced by Aβ peptides [68]. In the extra-
cellular matrix FGF2 competes with Aβ and APP for
binding sites on heparan sulfate proteoglycans [69,70].
This competitive binding by FGF2 may suppress intersti-
tial amyloid plaque formation. Because the interstitium
receives FGF2 from CSF, we predict that pharmacological
boosting of CP secretion of FGF2 would relieve AD.
FGF2-mediated protective regulation of CP transport phe-
nomena potentially affects the course of neurodegenera-
tion. Considerable evidence points to CP's ability to
remove Aβ from CSF [71-73]. This implicates reabsorptive
transport at the blood-CSF barrier to reduce CSF Aβ bur-
den in advanced AD. In clearing Aβ from the CNS, the CP
epithelium is exposed to substantial amounts of Aβ with
the potential to curtail energized ion transport and fluid
formation. CP Na-K-ATPase, a key enzyme in CSF produc-
tion [74], also enables the transport of organic com-
pounds [13]. Significantly, FGF2 lessens the toxicity of Aβ
on Na-K-ATPase activity and mitochondrial function in
cultured hippocampal neurons [68]. Toxic Aβ loads on CP
transporters might impair secretion. The resultant
decrease in CSF volume transmission and turnover would
further destabilize the CNS. However treatment of AD
with FGF analogs and IGF-1 [75] holds promise for coun-
tering Aβ toxicity [68] by creating a better CSF 'metabolic
environment' for CP and brain.
Fluid-regulating proteins
The diminished ability of CP to form fluid in advanced
ageing and AD begs the question of how epithelial ion
transport proteins are altered by distorted neurochemistry
in senescence. In very old laboratory mammals the Na-K-
ATPase activity of CP and the CSF generated by it are cut
in half [26,76]. Another ion-translocating protein coupled
to CSF formation is the apical NaK2Cl cotransporter
isoform1 (NKCC1). NKCC1 transports Na, K and Cl into
and out of the choroidal epithelium [77], depending
upon ion gradients and hormonal modulation. Versatile
bidirectional transport via NKCC1 confers flexibility for
regulating ion movements and concentrations in the CP-
CSF. Fluid secretion at the blood-CSF interface is linked to
ion fluxes mediated by the loop-diuretic sensitive NKCC1
[78,79]. NKCC1 information is plentiful for laboratory
animal CP-CSF [78-84] but scarce for the human
counterpart.
The cation-Cl superfamily of cotransporters includes
NKCC1 and consists of 7 isoforms that actively transport
Na and/or K electroneutrally with Cl [85]. NKCC1 in CP
has several functions, i.e., to regulate epithelial [Cl], stabi-
lize CSF [K] and control fluid secretion [77]. The T4 anti-
body differentially stains the NKCC1 secretory isoform in
the apical membrane but not the KCl isoform at the baso-
lateral surface of CP. In brain fluid homeostasis the
expression of NKCC1 in CP is likely sensitive to perturba-
tions in CSF osmolality, choroidal epithelial cell volume/
ion concentrations, intracranial pressure and ventricular
volume. To shed light on compensatory responses by the
CP to disease, our group analyzed NKCC1 expression in
congenital, high-pressure hydrocephalus; and in adult
chronic, closer-to-normal pressure hydrocephalus in AD/
NPH syndromes.
The NKCC1 helps cells and organs adjust to disrupted
fluid balance. One thus expects homeostatic upregulation
of this CP cotransporter in AD with its altered CSF dynam-
ics. For delineating NKCC1 expression we used the T4
antibody to immunostain CP at various stages of AD
dementia. Robust staining of the lateral ventricle plexusCerebrospinal Fluid Research 2004, 1:3 http://www.cerebrospinalfluidresearch.com/content/1/1/3
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(even at Braak stage V/VI) occurred in the apical mem-
brane and cytoplasm (Fig. 4). In an earlier study of CP
specimens from various mammalian species (unpub-
lished data), we observed uniform and consistent staining
of the apical membrane NKCC1. T4 staining of the cyto-
plasm was more variable. In the human CPs analyzed,
however, there was consistent cytoplasmic staining in AD
and age-matched controls (Fig. 4). This may represent
cytoplasmic NKCC1 protein available for insertion into
the apical membrane.
NaK2Cl cotransporter expression in human CP: Lateral ventricle plexuses were incubated with T4 (not thyroxine) antibody,  which stains the secretory isoform 1 of the NaK2Cl (NKCC1) cotransporter protein Figure 4
NaK2Cl cotransporter expression in human CP: Lateral ventricle plexuses were incubated with T4 (not thyroxine) antibody, 
which stains the secretory isoform 1 of the NaK2Cl (NKCC1) cotransporter protein. The T4 antibody (mouse monoclonal; 
1:100) was from the University of Iowa Developmental Studies Hybridoma Bank (Iowa City, IA); the biotinylated secondary 
was a rat-absorbed horse antibody. Diaminobenzidine was used to develop the brown reaction product. Controls (negative 
staining results; not shown) involved omission of secondary and/or primary antibody. AD tissues were from patients at Braak 
stage V/VI (top right) and III/IV (bottom right). Images are representative of 6 CPs analyzed for AD (mean age of 76 yr) and 6 
for age-matched controls (mean age of 76 yr). On average, the staining intensity of AD specimens was 50% greater than con-
trols. The text describes staining localization. All photographs are at the same magnification.Cerebrospinal Fluid Research 2004, 1:3 http://www.cerebrospinalfluidresearch.com/content/1/1/3
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AD choroidal tissues had greater T4 staining than controls
(Fig. 4). The apical NKCC1 (Fig. 5) is strategically posi-
tioned to sense physical changes in CSF resulting from AD
deterioration. Changes in pressure [86] or volume repre-
sent potential stimuli for inducing NKCC1 in CP. Ven-
triculomegaly and transient elevations in ICP in AD and
NPH may elicit a compensatory response in CP to down-
regulate CSF formation by promoting ion reabsorption
via the NKCC1 (Fig. 5). This scheme fits the enhanced
expression of NKCC1 in CP of HTx congenital hydroceph-
alus rats with ventriculomegaly [87]. ANP, AVP, angi-
otensin II, serotonin and catecholamines all reduce CSF
formation rate [99]. Table 3 recapitulates the stimulating
effect of these same agents on NKCC1 transport activity in
various tissues [88-94]. This prompts the hypothesis that
CSF formation is decreased secondarily to enhanced
reabsorptive uptake of Na, K and Cl by CP from CSF (Fig.
5). Information about protein levels and mRNA for
NKCC1 should relate CP cotransporter expression with
CSF dynamics, ICP and ventricular volume.
Other factors must be considered in interpreting the
enhanced NKCC1 expression (Fig. 4). An alternative but
not mutually exclusive explanation is that upregulated
NKCC1 in AD helps to counter cell shrinkage [95] in CP
(Table 2). Moreover, a rise in CSF [K] resulting from neu-
ronal damage, would be buffered by the NKCC1 [77] and
Na pump [96] in CP. Therefore it is possible that NKCC1
in CP is concurrently carrying out several physiologic
responses to stresses imposed by aging and disease. The
ventriculomegaly and reduced CSF formation rate
observed in AD and NPH [4] are consistent with the
upregulated NKCC1 in human CP. To corroborate the
model, however, more data are needed for humans and
animals to tightly link alterations in CP transport and
fluid turnover with AD progression. Because HSP90 binds
to NKCC1 and modulates its function [97], it is also of
interest to explore how upregulated HSP90 in AD (Fig. 2)
mechanistically relates to enhanced expression of NKCC1
(Fig. 4).
The choroid plexus as a 'bioreactor' to brain diseases
CP is highly equipped, homeostatically speaking, to help
the brain adapt to the metabolic distortions of dementia.
Injured neurons undergo compositional changes. These
cellular perturbations are transmitted to the extracellular
space and distort the interstitial fluid composition. Many
catabolites in the interstitium eventually gain access to the
ventricles where they contact the CPs. By accepting a host
of CSF-borne molecules, for either transport or receptor
stimulation, the CP mediates a wide scope of renal- and
hepatic-like activities [13,98]. This epithelial interface also
integrates many neurohumoral activities of the endocrine
and immune systems [98,99]. Diseases afflicting the CNS
generate injury metabolites and cytokines that are con-
veyed to the ependyma, pia-glia, arachnoid membrane
and CP epithelium. These interfaces handle catabolites
and peptide fragments [100] by reabsorbing them into the
systemic circulation for clearance or by sequestering toxic
substances in lysosomes for metabolic conversion. Harm-
ful substances are thereby effectively removed from the
brain-CSF system.
Signaling molecules are also carried by CSF from diseased
regions to the CP. There they bind to specific receptors in
the apical membrane and consequently elicit a variety of
bioreactive responses. Binding sites for a wide array of
peptides, proteins and other organic substances abound
in the mammalian CP [73]. Choroidal epithelial cells can
thus be regarded as 'bioreactors' that respond to chemical
changes in extracellular fluid. Their response includes the
synthesis of peptides, growth factors and sundry mole-
cules for homeostatically repairing injured neurons.
Currently, little is known about the spectrum of responses
by CP to the disrupted CNS homeostasis in AD. It would
be informative to compare AD stages for expression abili-
ties of CP vs. the ependyma and meninges. Differences as
well as similarities are anticipated. The initial studies of
gene expression in human CP reported herein reveal that
in Braak stages V/VI there is still strong expression of
HSP90 and NKCC1 (Figs. 2 &4). Therefore even though
the CP in advanced AD shows extensive histopathology
(Table 2) and has reduced enzymatic activities and fluid
formation [4,6,26], it evidently retains the ability to react
to biochemical perturbations by expressing housekeeping
proteins. This stabilizing effect on the blood-CSF barrier
epithelium enables regulatory phenomena that ultimately
support AD-stressed neurons.
Insight can be gained by investigating CSF neurochemical
composition as a function of AD severity. Additionally it
would be instructive to analyze how cultured CP
epithelium reacts to 'pathological' CSF from patients at
progressive Braak stages. The Z310 cultured cell line and
primary cultures of CP are useful for such analyses
[101,102]. Given the significance of CP in facilitating
repair of CNS structures, it should also be fruitful to ana-
lyze in vivo gene expressions that reflect pathophysiolog-
ical interactions between CP-CSF and brain.
How can CP and the regions it nourishes be protected from 
AD?
Therapeutic strategies to halt CNS deterioration should
include ways to defend the CP epithelium against the oxi-
dative ravages of ageing and AD. Prolonging CP viability
and work efficiency may be important in maintaining the
well being of geriatric patients. Even without a cure for
AD, if deleterious changes in the brain interstitium were
minimized in the elderly by stabilizing the CP-CSF (asCerebrospinal Fluid Research 2004, 1:3 http://www.cerebrospinalfluidresearch.com/content/1/1/3
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well as the BBB), then it might be feasible to prevent the
early manifestations of AD (Braak stages I/II) from inten-
sifying into the debilitating pathology of V/VI.
One class of agents with considerable potential for AD
therapeutics is the growth factor group. A useful paradigm
for CSF growth factors and neuroprotection has evolved
from experiments on transient forebrain ischemia in rats
A working model for hydrocephalus-induced alterations in NKCC1 cotransporter expression in CP: Ion transport across baso- lateral and apical surfaces is driven by transmembrane ion gradients [74, 83] Figure 5
A working model for hydrocephalus-induced alterations in NKCC1 cotransporter expression in CP: Ion transport across baso-
lateral and apical surfaces is driven by transmembrane ion gradients [74, 83]. Normally the net transport of Na, K, Cl, and 
HCO3 from choroid cell into CSF is integral to CSF production [5, 7]. However, we postulate that when CSF formation is 
inhibited by various neurohumoral agents there is stimulated (+) inward NaK2Cl flux from CSF into the cell; this would 
increase cytoplasmic Na and Cl concentration [77] thus creating a less favorable ion gradient for basolateral uptake of Na and 
Cl from plasma. Consequently, there is inhibited (-) basolateral ion uptake, and sequentially, reduced apical extrusion of Na 
into CSF [40]. Net effect = decreased CSF formation. Consistent with this idea are observations of enhanced expression of CP 
NKCCl in congenital hydrocephalus [87] and AD (Fig. 4), both of which are generally associated with lower rates of CSF for-
mation. Agents in Table 3 (e.g., Ang II) simultaneously stimulate the inward and outward arms of NKCC1, but the former three 
times the latter, resulting in net inward flux of ions [discussed in ref. 93]. The model thus vectorially emphasizes the inward 
arm of the NKCC1 (large arrowheads) as the one primarily stimulated by agents that suppress CSF formation. We hypothesize 
that in hydrocephalus, with increased intracranial pressure and/or ventriculomegaly, there is an associated attenuation of fluid 
output by CP.Cerebrospinal Fluid Research 2004, 1:3 http://www.cerebrospinalfluidresearch.com/content/1/1/3
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[59,60]. The TFI experiments characterized the destructive
effects of acute ischemia on the lateral ventricle CP and
the nearby CA1 region of hippocampus [50]; and the time
course of cell recovery (or death) in these adjacent regions
protected (or not) by supplemental infusion of FGF2 via
CSF prior to the ischemic insult [61]. Exogenous FGF2
administered before or after the induced ischemia less-
ened cell death in CA1, probably in part by stabilizing CP
functions [28,50,61]. Moreover the CP substantially
repaired its epithelial cell barrier by 24 hr post-TFI, even
without supplemental FGF2 [60]. Collectively these find-
ings manifest the impressive plasticity of CP to reconsti-
tute itself after disruption; and reveal the potential
therapeutic value of pharmacologically-administered
growth factors to reduce harm to CP and hippocampus.
Several other growth factors synthesized by CP and
secreted into CSF should be explored in translational
research dealing with interacting ischemia, hydrocephalus
and AD [1,4,6,28,36,50,55,103,104]. Following TFI the
CP upregulates TGFβ, another peptide that helps the CNS
adjust to injury [58]. Consequently choroidally-manufac-
tured growth factors in disease states can benefit the
plexus locally (by autocrine and paracrine mechanisms)
and the brain more globally (by endocrine-like bulk flow
of CSF). Our ischemia findings for the CP-CSF-hippocam-
pus compartments [27,58,60] relate to AD in that reduced
blood flow to the ageing CNS exacerbates AD progression.
Growth factor supplements (e.g., VEGF, NGF, IGF-II &
HGF) could augment viability in AD-vulnerable regions
by enhancing vascularization, preventing programmed
cell death or promoting stem cell conversion in the sub-
ventricular zone (SVZ). Newly-formed neurons in the SVZ
might then migrate to atrophic regions to replace
destroyed cells. One pharmacologic approach to stall AD
onset is to administer a combination of growth factors
designed to increase neuroprotection while minimizing
fibrosis [55]. We theorize that an optimal regimen of
growth factors and neuropeptides would restore CP func-
tion or prevent further loss of homeostatic capabilities.
A look towards pharmacologic manipulation of CP in AD 
dementia
In searching for agents to modify CP epithelial protein
expression, the route of delivery of the active drug is of pri-
mary importance. Unlike the brain with its impermeable
microvessels, the CP readily takes up water-soluble drugs
from the plasma due to the highly-permeable choroidal
capillaries. Consequently water-soluble agents freely
diffuse to receptors or binding sites at the basolateral sur-
face of the epithelium. Access of blood-borne hydrophilic
compounds to the CSF-side of CP however is problematic
because the tight junctions and basolateral membrane
impede diffusing molecules as small as mannitol [105].
Molecular sieving at the basolateral membrane restricts
the permeation of hydrophilic molecules as small as urea
(m.w. = 60) into the CP-CSF compartments [106].
To circumvent the blood-CSF barrier, therapeutic agents
are delivered into CSF by lateral ventricle catheters in
experimental animals [55] or hydrocephalic patients.
Gene therapy offers the additional challenge of finding a
viral vector that selectively targets the CP epithelium for
transduction [107]. Timely, innovative strategies are in
order to find specific ways to target and improve CP func-
tion in neurodegenerative states.
Table 3: Stimulation of NaK2Cl cotransport by hormones, neurotransmitters and peptides that inhibit choroid plexus-CSF formation
Active agent Model Species Cotransport activitya Reference
Atrial natriuretic peptide Neuroblastoma Human  82% 88
Angiotensin II Aortic endothelium Cow  38% 94
Arginine vasopressin Medullary TALb Mouse  66% 89
Serotonin agonistc Fibroblasts Cell line  49% 90
Adrenergic agoniste Parotid gland epithelium Rat  R5 stainingd 91
Adrenergic agoniste Skeletal muscle (plantaris) Rat  1700% 92
Basic fibroblast growth 
factor
Aortic endothelium Cow
 40%
93
a Bumetanide-sensitive 86Rb uptake by cells
b Thick ascending limb of kidney tubule
c (-)-2,5-dimethoxy-4-bromoamphetamine
d R5 antibody-detected phosphorylation of NKCC1 proportional to functional activity
e Isoproterenol
⇑
⇑
⇑
⇑
⇑
⇑
⇑Cerebrospinal Fluid Research 2004, 1:3 http://www.cerebrospinalfluidresearch.com/content/1/1/3
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A compelling aspect of CSF translational research is to
identify agents that effectively regulate fluid formation by
CP. Whereas the difficulty in congenital hydrocephalus is
to downregulate CSF formation, the challenge in AD is to
enhance CSF turnover perhaps by accelerating fluid pro-
duction as well as outflow. Augmented flow of CSF
enhances 'sink action' [108,109]. This would expedite
clearance of toxic molecules like Aβ out of the brain inter-
stitial fluid into the ventricles. New agents that stimulate
CP to secrete CSF more rapidly should be tested in aged
animals and those with AD-phenotypes. A consistent
finding of decreased CNS burdens of Aβ in animals with
increased CSF turnover could spur the development of
drugs for brain 'cleansing' in AD.
Another CP pathology meriting pharmacological atten-
tion is the massive fibrosis that progressively envelops the
interstitium in old age. This interstitial fibrosis is even
more extensive in AD [21]. Fibrosis undoubtedly impedes
efficient movement of molecules between blood and CSF.
It is pertinent to ascertain if therapeutic minimization of
CP fibrosis in later life would permit a brisk turnover of
CSF to be sustained. Attenuating the formation of Biondi
bodies and other choroidal cellular inclusions (Table 2)
would be a unique approach to prevent age- and disease-
related curtailment of CSF production. Optimal vascular-
interstitial-epithelial interactions in the CP are founda-
tional for vigorous CSF dynamics. The longer the blood-
CSF interface retains its epithelial secretory capabilities,
the more successfully it can conduct homeostatic activities
to ward off AD.
Recapitulation and projections
The CP has the main responsibility for CSF homeostasis.
Therefore the functional status of the blood-CSF barrier is
of great consequence to the CNS. Maintaining the CSF at
a stable, specialized composition is of the utmost impor-
tance to neurons. CSF is prominent in regulating brain
interstitial fluid with which it exchanges nutrients and
waste products. Diseases markedly affect these molecular
exchanges. Maintaining healthy bidirectional transport
across the CP epithelium (CSF-blood) and ependyma
(CSF-brain) is thus integral to a sound brain fluid
environment.
CSF macrocirculation through the ventriculo-subarach-
noid system together with CSF microcirculation in the
perivascular Virchow-Robin spaces [110,111] perform
distributive as well as collective functions. By gathering
waste products, the CSF is a quasi-lymphatic system with
critical functions in excreting harmful peptides and pro-
teins. In early life the upregulated secretions of CP play a
central role in brain ontogeny by furnishing growth fac-
tors to the germinal matrix. At the end of life with disease
onset or aging consequences, the CP transporters are
upregulated again to rescue failing neurons by providing
neurotrophic materials to CSF. Equally important, pep-
tides in excess such as amyloid beta (Aβ) fragments in AD
must be eliminated from CNS by perivascular pathways
[112]. To facilitate clearance of Aβ, the continual produc-
tion of CSF by CP sustains 'sink action' on the brain inter-
stitium [109].
As the main generator of CSF, the CP has a pivotal role in
helping the brain cope with the twin stressors of ageing
and disease. More attention should be focused on the
blood-CSF interface for pharmacologic opportunities to
stave off CP dysfunction. Our findings on human CP
expression of HSP90, FGFr and NKCC1 demonstrate that
this epithelium in AD reacts to metabolic insults by upreg-
ulating certain proteins. This suggests that even diseased
CP could respond to therapeutic agents, thus opening new
vistas for treating CSF dysfunction in age-related
dementias.
Conclusions
Investigation of CP in AD is an area that is opening up.
Translational research can now intensely focus on molec-
ular factors that disable the CP to the point of reducing its
ability to preserve brain integrity. Systematic CSF analyses
using mass spectrometry and other cutting-edge biotech-
nology should generate neurochemical data specific for
disease stages. New imaging approaches are essential to
provide much needed functional data for CP, CSF and
periventricular regions in AD patients. This should expe-
dite the modeling of CP-CSF malfunctions and their reso-
lution. Deeper insight into the pathophysiology of the
blood-CSF transport interface will help to realize the
development of novel therapeutic regimens for the AD
family of diseases.
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